<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00610480</url>
  </required_header>
  <id_info>
    <org_study_id>092007-002</org_study_id>
    <nct_id>NCT00610480</nct_id>
  </id_info>
  <brief_title>Tear Film Stability After Instillation of Over-the-Counter (OTC) Artificial Drops</brief_title>
  <official_title>Effects of Systane® Versus Optive™ Lubricating Eye Drops in Maintaining Tear Film Stability at Determined Time Points</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this research is to evaluate and compare the effectiveness of Systane® versus&#xD;
      Optive™ on aqueous tear film stability in patients with a diagnosis of Dry Eye Syndrome and&#xD;
      to determine the possible application for this product in the future. Systane® is marketed as&#xD;
      over-the-counter tear lubricating therapy in the United States under the FDA monograph.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Twenty (20) patients will be enrolled in this two-period crossover, randomized study design.&#xD;
      During the course of the study, each patient will be treated with each test article in the&#xD;
      clinic at separate visits. Following the informed consent procedure, a general ocular&#xD;
      evaluation, including corneal and conjunctival staining and Schirmer testing, will be done&#xD;
      and evaporometry assessments will be completed to determine baseline tear evaporation rate.&#xD;
      This will occur before any test article is administered to the patient.&#xD;
&#xD;
      Qualified patients will be randomized into two treatment groups. After 1 hour, in order to&#xD;
      eliminate any residual sodium fluorescein, patients will be administered one drop of Systane®&#xD;
      (40 µl) or Optive™ (40 µl) in each eye per randomization assignment. At 30 minutes following&#xD;
      instillation of the drop, the evaporometry measurement will be repeated. These evaporometry&#xD;
      tests (pre and post instillation of drops) will be performed in order to establish a&#xD;
      comparison for later analysis. The estimated time in completing each study visit will be 180&#xD;
      minutes per visit. Patients will be asked to return to the clinic after 2 - 14 days for&#xD;
      evaluation of the 2nd assigned crossover treatment (i.e. patients who initially received&#xD;
      Optive will receive Systane and patients who initially received Systane will receive Optane).&#xD;
&#xD;
      During the interim study periods, patients will be asked to continue their pre-study routine;&#xD;
      using their pre-study ocular lubricant or other tear products at the same frequency. Any&#xD;
      changes in the frequency of product use during the interim period or any changes in other&#xD;
      concomitant medications will be carefully recorded. This is especially important since many&#xD;
      prescription products (e.g., Claritan) have significant effects on lacrimal gland physiology.&#xD;
&#xD;
      An effort will be made to schedule all study visits at approximately the same time of day in&#xD;
      order to reduce diurnal variability. For the similar reasons, all patients will be asked not&#xD;
      to use any lubricants or ocular medications for at least one hour prior to their office&#xD;
      visits.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Aqueous Tear Evaporation Rate Before and After Use of OTC Artificial Tears</measure>
    <time_frame>Baseline and 30 minutes after artificial tear instillation</time_frame>
    <description>To evaluate the effect of OTC artificial tears on tear film stability, the evaporation rate (µl/cm2/min) will be determined with an Evaporometer for the left eye only of each patient. For each arm, the evaporation rates will be determined at baseline and at 30 minutes after installation of artificial tears. Evaporation rates in all cases will be determined under two different relative humidity (RH) conditions, RH from 25-35% and RH from 35-45%.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Dry Eye Disease</condition>
  <arm_group>
    <arm_group_label>Optive, then Systane Artificial Tears</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Artificial Tears (Optive, 40 microliters) will be administered at the first study visit, after baseline evaporation rate measurements have been taken. Evaporation rate measurements will be repeated 30 minutes later. At the next study visit, 2-14 days later, artificial tears (Systane, 40 microliters) will be administered using the same procedure protocol.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Systane, then Optive Artificial Tears</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Artificial Tears (Systane, 40 microliters) will be administered at the first study visit, after baseline evaporation rate measurements have been taken. Evaporation rate measurements will be repeated 30 minutes later. At the next study visit, 2-14 days later, artificial tears (Optive, 40 microliters) will be administered using the same procedure protocol.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1st visit Optive, then 2nd visit Systane</intervention_name>
    <description>First visit: Instillation of Optive followed by evaporometry assessment after 30 minutes.&#xD;
Second visit: Instillation of Systane followed by evaporometry assessment after 30 minutes.</description>
    <arm_group_label>Optive, then Systane Artificial Tears</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1st visit Systane, then 2nd visit Optive</intervention_name>
    <description>First visit: Instillation of Systane followed by evaporometry assessment after 30 minutes.&#xD;
Second visit: Instillation of Optive followed by evaporometry assessment after 30 minutes.</description>
    <arm_group_label>Systane, then Optive Artificial Tears</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Individuals aged 18 and up will be included, where any age over 89 will be recorded as&#xD;
             'greater than 89.'&#xD;
&#xD;
          -  Individuals with bilateral eye sight eye correctable to 20/80 or better.&#xD;
&#xD;
          -  Individuals in good health with or without Meibomian Gland Dystrophy (MGD) but with&#xD;
             Aqueous Tear Deficiency (ATD) with minimal to no ocular surface inflammation on slit&#xD;
             lamp examination.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Individuals with only one sighted eye or vision not correctable to 20/80 or better in&#xD;
             both eyes.&#xD;
&#xD;
          -  Individuals with history of punctal plugs or punctal occlusions.&#xD;
&#xD;
          -  Individuals with history of keratorefractive as well as ophthalmic disease such as&#xD;
             corneal dystrophies, glaucoma, or systemic disease affecting the eye (such as Herpes&#xD;
             Zoster).&#xD;
&#xD;
          -  Individuals with history of systemic or ocular auto-immune conditions.&#xD;
&#xD;
          -  Individuals with active systemic disease or those taking systemic medication that are&#xD;
             known to influence AT production will not be considered for this trial.&#xD;
&#xD;
          -  Individuals using topical medication who are unable to discontinue them for at least&#xD;
             24 hours prior to baseline evaluation will be excluded as well.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vinod Mootha, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UTSW Medical Center at Dallas</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UTSW Medical Center at Dallas - Aston Ambulatory Care Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390-9057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>January 27, 2008</study_first_submitted>
  <study_first_submitted_qc>February 7, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 8, 2008</study_first_posted>
  <results_first_submitted>December 20, 2018</results_first_submitted>
  <results_first_submitted_qc>October 28, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">November 19, 2020</results_first_posted>
  <last_update_submitted>October 28, 2020</last_update_submitted>
  <last_update_submitted_qc>October 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Texas Southwestern Medical Center</investigator_affiliation>
    <investigator_full_name>V. Vinod Mootha</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Dry Eyes</keyword>
  <keyword>Tear Film Stability</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Eye Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects with dry eye disease will be recruited from Ophthalmology clinic patients and otherwise healthy volunteers who are students or employees of the University of Texas Southwestern Medical Center.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Optive, Then Systane Artificial Tears</title>
          <description>Artificial Tears (Optive, 40 microliters) will be administered at the first study visit, after baseline evaporation rate measurements have been taken. Evaporation rate measurements will be repeated 30 minutes later. At the next study visit, 2-14 days later, a baseline evaporation rate will be measured, artificial tears (Systane, 40 microliters) will be administered, and evaporation rate measurements will be repeated 30 minutes later.</description>
        </group>
        <group group_id="P2">
          <title>Systane, Then Optane Artificial Tears</title>
          <description>Artificial Tears (Systane, 40 microliters) will be administered at the first study visit, after baseline evaporation rate measurements have been taken. Evaporation rate measurements will be repeated 30 minutes later. At the next study visit, 2-14 days later, a baseline evaporation rate will be measured, artificial tears (Optane, 40 microliters) will be administered, and evaporation rate measurements will be repeated 30 minutes later.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10">10 assigned patients x 2 interventions.</participants>
                <participants group_id="P2" count="10">10 assigned patients x 2 interventions.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10">10 assigned patients x 2 interventions.</participants>
                <participants group_id="P2" count="10">10 assigned patients x 2 interventions.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Optive, Then Systane</title>
          <description>Artificial Tears (Optive, 40 microliters) will be administered at the first study visit, after baseline evaporation rate measurements have been taken. Evaporation rate measurements will be repeated 30 minutes later. At the next study visit, 2-14 days later, a baseline evaporation rate will be measured, artificial tears (Systane, 40 microliters) will be administered, and evaporation rate measurements will be repeated 30 minutes later.</description>
        </group>
        <group group_id="B2">
          <title>Systane, Then Optive</title>
          <description>Artificial Tears (Systane, 40 microliters) will be administered at the first study visit, after baseline evaporation rate measurements have been taken. Evaporation rate measurements will be repeated 30 minutes later. At the next study visit, 2-14 days later, a baseline evaporation rate will be measured, artificial tears (Optane, 40 microliters) will be administered, and evaporation rate measurements will be repeated 30 minutes later.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Aqueous Tear Evaporation Rate Before and After Use of OTC Artificial Tears</title>
        <description>To evaluate the effect of OTC artificial tears on tear film stability, the evaporation rate (µl/cm2/min) will be determined with an Evaporometer for the left eye only of each patient. For each arm, the evaporation rates will be determined at baseline and at 30 minutes after installation of artificial tears. Evaporation rates in all cases will be determined under two different relative humidity (RH) conditions, RH from 25-35% and RH from 35-45%.</description>
        <time_frame>Baseline and 30 minutes after artificial tear instillation</time_frame>
        <population>Total participant enrollment is 20 (3 men and 17 women). Ten participants were assigned to each sequence, so a total of 20 participants experienced each intervention.</population>
        <group_list>
          <group group_id="O1">
            <title>Optive Artificial Tears</title>
            <description>Artificial Tears (Optive, 40 microliters) will be administered at the first study visit, after baseline evaporation rate measurements have been taken. Evaporation rate measurements will be repeated 30 minutes later. At the next study visit, 2-14 days later, a baseline evaporation rate will be measured, artificial tears (Systane, 40 microliters) will be administered, and evaporation rate measurements will be repeated 30 minutes later.</description>
          </group>
          <group group_id="O2">
            <title>Systane Artificial Tears</title>
            <description>Artificial Tear&#xD;
Artificial Tears (Systane, 40 microliters) will be administered at the first study visit, after baseline evaporation rate measurements have been taken. Evaporation rate measurements will be repeated 30 minutes later. At the next study visit, 2-14 days later, a baseline evaporation rate will be measured, artificial tears (Optane, 40 microliters) will be administered, and evaporation rate measurements will be repeated 30 minutes later.</description>
          </group>
        </group_list>
        <measure>
          <title>Aqueous Tear Evaporation Rate Before and After Use of OTC Artificial Tears</title>
          <description>To evaluate the effect of OTC artificial tears on tear film stability, the evaporation rate (µl/cm2/min) will be determined with an Evaporometer for the left eye only of each patient. For each arm, the evaporation rates will be determined at baseline and at 30 minutes after installation of artificial tears. Evaporation rates in all cases will be determined under two different relative humidity (RH) conditions, RH from 25-35% and RH from 35-45%.</description>
          <population>Total participant enrollment is 20 (3 men and 17 women). Ten participants were assigned to each sequence, so a total of 20 participants experienced each intervention.</population>
          <units>(µl/cm2/min)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline:25-35%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.047" spread="0.019"/>
                    <measurement group_id="O2" value="0.049" spread="0.023"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline:35-45%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.031" spread="0.014"/>
                    <measurement group_id="O2" value="0.032" spread="0.016"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 minutes:25-35%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.052" spread="0.024"/>
                    <measurement group_id="O2" value="0.051" spread="0.025"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 minutes:35-45%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.034" spread="0.016"/>
                    <measurement group_id="O2" value="0.032" spread="0.014"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected for each participant for up to 2 weeks, from time of enrollment to completion of study visits,</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Optive Artificial Tears</title>
          <description>Artificial Tears (Optive, 40 microliters) will be administered at the first study visit, after baseline evaporation rate measurements have been taken. Evaporation rate measurements will be repeated 30 minutes later.</description>
        </group>
        <group group_id="E2">
          <title>Systane Artificial Tears</title>
          <description>Artificial Tears (Systane, 40 microliters) will be administered at the first study visit, after baseline evaporation rate measurements have been taken. Evaporation rate measurements will be repeated 30 minutes later.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Peter Chen</name_or_title>
      <organization>UT Southwestern Medical Center</organization>
      <phone>214-648-3837</phone>
      <email>peter.chen@utsouthwestern.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

